Unveiling the latest insights on KRAS+ NSCLC, join Dr. Jia Luo, an esteemed Medical Oncologist at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard, in this riveting session from the 2022 Targeted Therapies Forum. Dr. Luo delves deep into the nuances of managing KRAS Mutated NSCLC, exploring state-of-the-art treatment strategies to benefit patients diagnosed with KRAS+ NSCLC.
A special thank you to our generous sponsors for their support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.
Stay at the forefront of oncological advancements. Dive deeper into our resources at http://cancerGRACE.org/. Engage with pioneers in the field and be part of the conversation at https://cancergrace.org/forum.